Perioperative Safety and Effectiveness of Laparoscopic Heller Myotomy in Elderly Patients: Systematic Review and Meta-Analysis.

Surg Laparosc Endosc Percutan TechOct 1, 2026 (epub)
Clinical ResearchGeriatricsGeneral Surgery

José Barros Sosa, Cristian A Angeramo, Josefina Príncipe et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the perioperative safety and effectiveness of laparoscopic Heller myotomy (LHM) in patients aged 65 years or older. Analyzing 6 studies with 275 patients, the findings indicated that LHM is safe, with intraoperative complications occurring in 6% of cases and a dysphagia improvement rate of 96%.

Key findings

  • Intraoperative complications occurred in 6% of patients, all mucosal perforations.
  • Overall morbidity rate was 8%, with no reported perioperative mortality.
  • Dysphagia improvement was achieved in 96% of patients.
  • Postoperative reintervention was needed in only 14% of patients.

Why it matters

Understanding the safety and effectiveness of laparoscopic Heller myotomy in elderly patients is crucial for clinicians, as it informs treatment decisions for achalasia in this population, balancing potential risks and benefits.

Source

PubMed · PMID 42441948

Published in Surg Laparosc Endosc Percutan Tech. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.